U.S. Software Stock News

NYSE:JXN
NYSE:JXNDiversified Financial

Jackson Financial (JXN): Revisiting Valuation After Strong Multi‑Year Shareholder Returns

Jackson Financial (JXN) has quietly put up solid numbers, with annual revenue and net income both growing around 9% and 14%. That kind of steady progress is starting to draw more valuation-focused attention. See our latest analysis for Jackson Financial. The stock has backed that earnings momentum with a strong 30 day share price return of 14.66 percent and an impressive three year total shareholder return of 252.93 percent, suggesting momentum is still firmly on Jackson Financial's side. If...
NYSE:PERF
NYSE:PERFSoftware

How Perfect’s AI Beauty APIs and Developer Pivot Could Reframe the Long-Term Case for PERF Investors

In December 2025, Perfect Corp. announced it will showcase a new generation of AI beauty agents and a modular, consumption-based API suite at CES 2026, aimed at powering personalized, cross-channel experiences for brands of all sizes. The move signals a push to become an infrastructure provider for beauty and retail AI, shifting from standalone apps toward developer-first tools that can embed Perfect’s technology across e-commerce, mobile, and in-store journeys. We’ll now examine how...
NYSE:TBBB
NYSE:TBBBConsumer Retailing

Assessing BBB Foods (NYSE:TBBB) Valuation After Strong Sales Beat and Rapid Expansion Momentum

BBB Foods (NYSE:TBBB) just posted quarterly results that turned heads, with sales jumping 37% and EBITDA margins near the top of expectations, supported by rapid store expansion and standout same store growth. See our latest analysis for BBB Foods. The strong quarter seems to be feeding into the narrative, with a 90 day share price return of 35.68 percent and year to date share price gains of 18.34 percent. This suggests momentum is clearly building off these growth signals. If this kind of...
NasdaqGM:RAPT
NasdaqGM:RAPTBiotechs

RAPT Therapeutics (RAPT): Evaluating Its Rich Valuation After TD Cowen’s Bullish Initiation and Phase 2 Progress

RAPT Therapeutics (RAPT) has been back on traders’ screens after TD Cowen kicked off coverage with a positive stance, following upbeat Phase 2 data for ozureprubart and fresh FDA clearance for a Phase 2b food allergy trial. See our latest analysis for RAPT Therapeutics. That backdrop has helped fuel a sharp re-rating, with the stock delivering a 179.68 percent year to date share price return and a 162 percent one year total shareholder return, even as the five year total shareholder return...
NasdaqCM:CDRO
NasdaqCM:CDROHospitality

Codere Online (NasdaqCM:CDRO) One-Off Gain-Driven Profit Challenges Bullish Earnings Narrative

Codere Online Luxembourg (NasdaqCM:CDRO) has reported its H1 2025 results with total revenue of about €203.9 million over the trailing twelve months and basic EPS of €0.02, supported by net income of just over €1.0 million. The company has seen revenue move from €189.1 million to €203.9 million on a trailing twelve month basis, while EPS has shifted from a loss of €0.05 to a modest profit of €0.02. This highlights how small changes in profitability can meaningfully affect margins in this kind...
NYSE:CUBI
NYSE:CUBIBanks

Does Customers Bancorp’s 62.5% 2025 Rally Still Leave Room for Investors?

Wondering if Customers Bancorp is still worth buying after its big run, or if most of the upside is already priced in? You are not alone. The stock has climbed 4.9% over the last week, 16.9% in the past month, and is now up an impressive 62.5% year to date, building on multi year gains of 60.5% over 1 year, 172.9% over 3 years, and 323.9% over 5 years. These moves have come alongside a shift in market sentiment toward regional banks, as investors have grown more comfortable with funding and...
NYSE:GRND
NYSE:GRNDInteractive Media and Services

Grindr (GRND): Taking Stock of Valuation After Recent Share Price Pullback

Grindr (GRND) has quietly drifted this month, but its longer track record, including a strong 3 year return, makes the current pullback worth a closer look for patient, risk tolerant investors. See our latest analysis for Grindr. The stock has bounced 6.2 percent on a 7 day share price return, but that sits against a weaker year to date share price trend and a still impressive 3 year total shareholder return. This suggests momentum has cooled while the longer term growth story remains...
NYSE:MHK
NYSE:MHKConsumer Durables

Is Mohawk Industries Attractively Priced After Housing Cycle Weakness in 2025?

If you have been wondering whether Mohawk Industries at around $108 a share is a bargain or a value trap, you are not alone. This article is designed to cut through the noise and focus squarely on what the numbers say. The stock is down about 2.6% over the last week, roughly 1.2% over the last month, and about 6.3% year to date, while still sitting on a 10.8% gain over three years despite a 22.7% slide over five years. Recent headlines have centered on the housing and renovation cycle,...
NasdaqGM:AVDL
NasdaqGM:AVDLPharmaceuticals

How Completion of REVITALYZ Enrollment and Orphan Status at Avadel Pharmaceuticals (AVDL) Has Changed Its Investment Story

Avadel Pharmaceuticals has completed patient enrollment in REVITALYZ, its Phase 3 trial testing once-at-bedtime LUMRYZ for idiopathic hypersomnia, advancing the drug beyond its existing US FDA-approved use in narcolepsy. This milestone, paired with LUMRYZ’s Orphan Drug Designation in idiopathic hypersomnia, could meaningfully influence expectations for the drug’s long-term role in sleep medicine. We’ll now explore how completion of REVITALYZ enrollment, and the prospect of label expansion...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug

Innoviva, Inc. recently received US FDA approval for NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic to treat uncomplicated urogenital gonorrhea in adults and pediatric patients. This marks one of the first new FDA-approved treatments for gonorrhea in nearly twenty years, underscoring Innoviva’s role in addressing antibiotic resistance and unmet infectious disease needs. We’ll now explore how bringing a first-in-class, single-dose oral treatment for gonorrhea affects...
NasdaqCM:ABTC
NasdaqCM:ABTCSoftware

3 Undervalued Small Caps With Insider Action Across Global Markets

As the U.S. market experiences a resurgence with major stock indexes closing sharply higher for the second consecutive day, small-cap stocks are gaining attention amid this renewed risk appetite. In this dynamic environment, identifying promising small-cap opportunities involves looking at companies with solid fundamentals and potential growth catalysts that align well with current market trends.
NasdaqGS:AVPT
NasdaqGS:AVPTSoftware

Undervalued Equities That May Offer Value In December 2025

As the U.S. stock market experiences a resurgence with major indexes posting gains, driven by a rally in tech stocks, investors are increasingly looking for opportunities that may be undervalued. In this environment of renewed risk appetite and shifting sector performances, identifying stocks that offer strong fundamentals at attractive valuations becomes crucial for those seeking potential value in their portfolios.
NYSE:SE
NYSE:SEMultiline Retail

Li Auto And 2 More Growth Companies With Strong Insider Confidence

As the U.S. stock market experiences a resurgence, with major indexes like the S&P 500 and Nasdaq posting weekly gains amid a tech rally, investor confidence appears to be on the rise. In such an environment, growth companies with high insider ownership can signal strong internal belief in their long-term potential, making them attractive considerations for those looking to align with management's vision.
NYSE:DDL
NYSE:DDLConsumer Retailing

Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist

As of December 19, 2025, major stock indexes in the United States have shown a notable upswing, with the tech-heavy Nasdaq and benchmark S&P 500 posting weekly gains amid a continued rally in technology shares. This positive momentum in broader markets can create an intriguing backdrop for exploring investment opportunities across various sectors. Penny stocks, while often considered speculative due to their lower price points and smaller company profiles, remain relevant as they can offer...